Ascentage Pharma Group International (AAPG): מקדם מחיר להכנסות

The prospects of Ascentage Pharma Group (AAPG) depend on the international recognition of olverembatinib and expansion into the US. Historical P/S dynamics confirm market expectations, where the current parameter equals 8.50. Growth is based on the global promotion of targeted drugs and alliances with big pharma. A positive forecast is supported by the development of apoptosis inhibitors aimed at combating tumor resistance within the framework of innovative R&D.

To isolate fundamental stability from market noise, the ratio of market capitalization to annual sales is utilized, allowing for the valuation of each unit of revenue without accounting distortions. Analyzing the price-to-sales multiple helps align current investor expectations with the commercialization potential of olverembatinib and the expansion prospects of Ascentage Pharma Group (AAPG) into the US market.